EP3256474A1 — Ibrutinib sulphate salt
Assigned to Zentiva KS · Expires 2017-12-20 · 8y expired
What this patent protects
The invention relates to a solid form of the salt of l-[(3 R -)-3-[4-amino-3-(4-phenoxyphenyl)- lH-pyrazolo[3,4-d]pyrimidin-l-yl]piperidin-l-yl]prop-2-en-l-one, known as ibrutinib, with sulphuric acid and a method of its preparation. Ibrutinib sulphate is in a crystalline form or…
USPTO Abstract
The invention relates to a solid form of the salt of l-[(3 R -)-3-[4-amino-3-(4-phenoxyphenyl)- lH-pyrazolo[3,4-d]pyrimidin-l-yl]piperidin-l-yl]prop-2-en-l-one, known as ibrutinib, with sulphuric acid and a method of its preparation. Ibrutinib sulphate is in a crystalline form or amorphous form.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.